TD Cowen raised the firm’s price target on Ginkgo Bioworks (DNA) to $16 from $12 and keeps a Buy rating on the shares. The firm said Cell Engineering drove the Q2 beat despite softer biosecurity revenues.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DNA: